Recent enforcement actions in several countries have targeted excessive pricing imposed by pharmaceutical companies. Competition agencies acknowledge the need to provide incentives for risky investments in developing new drugs, but also argue that selective intervention in the sector may be necessary. In this article, Margaret Kyle of MINES ParisTech discusses the methodologies, scope, and desirability of these interventions.
Previous article Britned Development V ABB: Are There Lessons to Be Learned on the Use of Economics and Econometrics in Cartel Damages? Next article Three Tech Competition Concerns